A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors

This clinical research study is being conducted to investigate the effectiveness of combining carboplatin and irinotecan, versus irinotecan alone, in treating children who have refractory solid tumors.

• children 1-21 years of age
• confirmed diagnosis of measurable solid tumor, including brain tumor, which has progressed on or after standard therapy, or for which no effective standard therapy is known
• at least 4 weeks since last dose of immunotherapy, radiotherapy, or chemotherapy
• no more than 3 prior chemotherapies
• no symptomatic brain metastases